SG Americas Securities LLC Purchases 220,264 Shares of Urogen Pharma $URGN

SG Americas Securities LLC increased its position in shares of Urogen Pharma (NASDAQ:URGN) by 19.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,377,647 shares of the company’s stock after purchasing an additional 220,264 shares during the period. SG Americas Securities LLC owned 2.94% of Urogen Pharma worth $32,264,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Osaic Holdings Inc. boosted its holdings in Urogen Pharma by 491.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after buying an additional 3,070 shares during the period. State of Wyoming bought a new stake in Urogen Pharma during the third quarter valued at about $66,000. Russell Investments Group Ltd. raised its holdings in Urogen Pharma by 1,594.4% during the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after acquiring an additional 3,125 shares during the period. Strs Ohio purchased a new position in shares of Urogen Pharma in the third quarter valued at about $76,000. Finally, CWM LLC boosted its stake in shares of Urogen Pharma by 18.0% in the third quarter. CWM LLC now owns 4,271 shares of the company’s stock worth $85,000 after acquiring an additional 650 shares during the period. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Urogen Pharma Trading Up 2.6%

Shares of Urogen Pharma stock opened at $18.12 on Thursday. The firm has a market cap of $882.08 million, a PE ratio of -5.66 and a beta of 1.34. The stock has a 50 day moving average of $19.94 and a 200 day moving average of $20.81. Urogen Pharma has a 12 month low of $3.42 and a 12 month high of $30.00.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.12. The firm had revenue of $37.84 million for the quarter, compared to analysts’ expectations of $39.92 million. As a group, equities research analysts forecast that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on URGN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, January 21st. Oppenheimer reaffirmed an “outperform” rating on shares of Urogen Pharma in a report on Monday, March 2nd. Finally, D. Boral Capital reiterated a “buy” rating and set a $33.00 price objective on shares of Urogen Pharma in a research report on Monday, March 2nd. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Urogen Pharma presently has a consensus rating of “Moderate Buy” and an average price target of $33.29.

Insiders Place Their Bets

In other Urogen Pharma news, General Counsel Jason Drew Smith sold 7,479 shares of Urogen Pharma stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total value of $147,261.51. Following the completion of the transaction, the general counsel directly owned 51,326 shares of the company’s stock, valued at $1,010,608.94. This trade represents a 12.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Mark Schoenberg sold 7,373 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total transaction of $145,174.37. Following the sale, the insider owned 144,985 shares in the company, valued at $2,854,754.65. This represents a 4.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 4.70% of the company’s stock.

Urogen Pharma Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.